|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM331594013 |
| 003 |
DE-627 |
| 005 |
20231225213814.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202106606
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1105.xml
|
| 035 |
|
|
|a (DE-627)NLM331594013
|
| 035 |
|
|
|a (NLM)34618380
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wang, Zijing
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Silk Microneedle Patch Capable of On-Demand Multidrug Delivery to the Brain for Glioblastoma Treatment
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 31.03.2022
|
| 500 |
|
|
|a Date Revised 01.04.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2021 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Surgery followed by chemotherapy and radiotherapy remains the standard treatment strategy for GBM patients. However, challenges still exist when surgery is difficult or impossible to remove the tumor completely. Herein, the design, fabrication and application of a heterogenous silk fibroin microneedle (SMN) patch is reported for circumventing the blood-brain barrier and releasing multiple drugs directly to the tumor site for drug combination treatment. The biocompatible and biodegradable SMN patch can dissolve slowly over time, allowing the sustained release of multiple drugs at different doses. Furthermore, it can be triggered remotely to induce rapid drug delivery at a designated stage after implantation. In the GBM mouse models, two clinically relevant chemotherapeutic agents (thrombin and temozolomide) and targeted drug (bevacizumab) are loaded into the SMN patch with individually controlled release profiles. The drugs are spatiotemporally and sequentially delivered for hemostasis, anti-angiogenesis, and apoptosis of tumor cells. Device application is non-toxic and results in decreased tumor volume and increased survival rate in mice. The SMN patch with on-demand multidrug delivery has potential applications for the combined administration of therapeutic drugs for the clinical treatment of brain tumors when other methods are insufficient
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a drug delivery
|
| 650 |
|
4 |
|a glioblastoma
|
| 650 |
|
4 |
|a microneedle patches
|
| 650 |
|
4 |
|a silk proteins
|
| 650 |
|
7 |
|a Silk
|2 NLM
|
| 650 |
|
7 |
|a Temozolomide
|2 NLM
|
| 650 |
|
7 |
|a YF1K15M17Y
|2 NLM
|
| 700 |
1 |
|
|a Yang, Zhipeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jiang, Jianjuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shi, Zhifeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mao, Ying
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Qin, Nan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tao, Tiger H
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 34(2022), 1 vom: 15. Jan., Seite e2106606
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:34
|g year:2022
|g number:1
|g day:15
|g month:01
|g pages:e2106606
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202106606
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 34
|j 2022
|e 1
|b 15
|c 01
|h e2106606
|